Two FDA panels are scheduled to review Elan Corp.'s and Biogen Idec's drug Tysabri in July as a possible treatment for Crohn's disease. Clinical trials indicate the drug, approved to treat multiple sclerosis, is effective in preventing inflammatory immune cells from penetrating intestinal walls.

Full Story:

Related Summaries